Lung cancer other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
| Line 20: | Line 20: | ||
|[[Image:IJRI-25-109-g006.jpg|thumb|300px|Role of FDG PET/CT in primary tumor delineation. Irregular soft tissue opacity seen on coronal CT scan (arrow, A) with no obvious demarcation between the tumor and surrounding consolidation. PET/CT shows the FDG-avid tumor (arrow, B) separate from the non–FDG-avid consolidation (arrowhead, B),via <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419420/figure/F6/>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.<ref name="PurandareRangarajan2015">{{cite journal|last1=Purandare|first1=NilenduC|last2=Rangarajan|first2=Venkatesh|title=Imaging of lung cancer: Implications on staging and management|journal=Indian Journal of Radiology and Imaging|volume=25|issue=2|year=2015|pages=109|issn=0971-3026|doi=10.4103/0971-3026.155831}}</ref>]] | |[[Image:IJRI-25-109-g006.jpg|thumb|300px|Role of FDG PET/CT in primary tumor delineation. Irregular soft tissue opacity seen on coronal CT scan (arrow, A) with no obvious demarcation between the tumor and surrounding consolidation. PET/CT shows the FDG-avid tumor (arrow, B) separate from the non–FDG-avid consolidation (arrowhead, B),via <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419420/figure/F6/>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.<ref name="PurandareRangarajan2015">{{cite journal|last1=Purandare|first1=NilenduC|last2=Rangarajan|first2=Venkatesh|title=Imaging of lung cancer: Implications on staging and management|journal=Indian Journal of Radiology and Imaging|volume=25|issue=2|year=2015|pages=109|issn=0971-3026|doi=10.4103/0971-3026.155831}}</ref>]] | ||
|[[Image:IJRI-25-109-g008.jpg|thumb|300px|FDG PET in nodal disease. Maximum intensity projection (MIP) image shows an FDG-avid primary lung tumor on the left side (arrow, A) and a focus of FDG uptake in the mediastinum (arrowhead, A). CT scan shows enhancing, spiculated primary tumor (arrow, B) and a small right paratracheal node (arrowhead, B) which is negative by size criteria. Fused PET/CT image shows FDG concentration in the primary (arrow, C) as well as the node (arrowhead, C), suggesting metastatic involvement. Mediastinoscopy and biospy revealed metastatic node-N3 disease,via <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419420/figure/F8/[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419420/figure/F9/ 9/]>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.<ref name="PurandareRangarajan2015">{{cite journal|last1=Purandare|first1=NilenduC|last2=Rangarajan|first2=Venkatesh|title=Imaging of lung cancer: Implications on staging and management|journal=Indian Journal of Radiology and Imaging|volume=25|issue=2|year=2015|pages=109|issn=0971-3026|doi=10.4103/0971-3026.155831}}</ref>]] | |[[Image:IJRI-25-109-g008.jpg|thumb|300px|FDG PET in nodal disease. Maximum intensity projection (MIP) image shows an FDG-avid primary lung tumor on the left side (arrow, A) and a focus of FDG uptake in the mediastinum (arrowhead, A). CT scan shows enhancing, spiculated primary tumor (arrow, B) and a small right paratracheal node (arrowhead, B) which is negative by size criteria. Fused PET/CT image shows FDG concentration in the primary (arrow, C) as well as the node (arrowhead, C), suggesting metastatic involvement. Mediastinoscopy and biospy revealed metastatic node-N3 disease,via <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419420/figure/F8/[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419420/figure/F9/ 9/]>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.<ref name="PurandareRangarajan2015">{{cite journal|last1=Purandare|first1=NilenduC|last2=Rangarajan|first2=Venkatesh|title=Imaging of lung cancer: Implications on staging and management|journal=Indian Journal of Radiology and Imaging|volume=25|issue=2|year=2015|pages=109|issn=0971-3026|doi=10.4103/0971-3026.155831}}</ref>]] | ||
|- | |||
| | |||
| | |||
|} | |} | ||
Revision as of 16:27, 16 February 2018
|
Lung cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lung cancer other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Lung cancer other diagnostic studies |
|
Risk calculators and risk factors for Lung cancer other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]
Overview
Other diagnostic studies include bone scintigraphy, PET scan, and molecular tests.
Lung Cancer Other Diagnostic Studies
Bone Scintigraphy
A bone scan may demonstrate bone metastases.
PET scan
- FDG(18 F fluoro deoxyglucose) PET scans along with contrast enhanced CT may be helpful in the diagnosis of extent of lung cancer. Findings on FDGPET/CT suggestive of lung cancer include:[1]
- Solitary pulmonary nodule
- Benefits of FDGPET/CT include:[2]
- Accurate delineation of the viable tumor from surrounding atelectasis and collapse or consolidation.
- It may further lead to a change in staging of the lung cancer.
- Provide guidance for the biopsy.[3]
 |
 |
Molecular Test
Molecular tests include epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present.
References
- ↑ 1.0 1.1 1.2 Purandare, NilenduC; Rangarajan, Venkatesh (2015). "Imaging of lung cancer: Implications on staging and management". Indian Journal of Radiology and Imaging. 25 (2): 109. doi:10.4103/0971-3026.155831. ISSN 0971-3026.
- ↑ van Baardwijk, Angela; Baumert, Brigitta G.; Bosmans, Geert; van Kroonenburgh, Marinus; Stroobants, Sigrid; Gregoire, Vincent; Lambin, Philippe; De Ruysscher, Dirk (2006). "The current status of FDG–PET in tumour volume definition in radiotherapy treatment planning". Cancer Treatment Reviews. 32 (4): 245–260. doi:10.1016/j.ctrv.2006.02.002. ISSN 0305-7372.
- ↑ Purandare, Nilendu C.; Kulkarni, Aniruddha V.; Kulkarni, Suyash S.; Roy, Diptiman; Agrawal, Archi; Shah, Sneha; Rangarajan, Venkatesh (2013). "18F-FDG PET/CT-directed biopsy". Nuclear Medicine Communications. 34 (3): 203–210. doi:10.1097/MNM.0b013e32835c5a57. ISSN 0143-3636.